These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 17391164

  • 1. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes.
    Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L, OBDM-003 Study Group.
    Diabetes Obes Metab; 2007 May; 9(3):360-8. PubMed ID: 17391164
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M.
    Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
    [Abstract] [Full Text] [Related]

  • 3. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
    Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, OBES-002 Study Group.
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
    Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A, OBD-202 Study Group.
    Diabetes Care; 2007 Jun; 30(6):1480-6. PubMed ID: 17363756
    [Abstract] [Full Text] [Related]

  • 5. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH.
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension.
    Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, Fitchet M.
    Am J Cardiol; 2005 Jul 15; 96(2):243-51. PubMed ID: 16018851
    [Abstract] [Full Text] [Related]

  • 7. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U.
    Int J Obes (Lond); 2007 Jul 15; 31(7):1140-7. PubMed ID: 17264849
    [Abstract] [Full Text] [Related]

  • 8. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, Troupin B.
    Diabetes Care; 2014 Dec 15; 37(12):3309-16. PubMed ID: 25249652
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.
    Clin Ther; 2008 Aug 15; 30(8):1448-60. PubMed ID: 18803987
    [Abstract] [Full Text] [Related]

  • 10. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.
    Astrup A, Caterson I, Zelissen P, Guy-Grand B, Carruba M, Levy B, Sun X, Fitchet M.
    Obes Res; 2004 Oct 15; 12(10):1658-69. PubMed ID: 15536230
    [Abstract] [Full Text] [Related]

  • 11. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
    O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR.
    Obesity (Silver Spring); 2012 Jul 15; 20(7):1426-36. PubMed ID: 22421927
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
    Winslow DH, Bowden CH, DiDonato KP, McCullough PA.
    Sleep; 2012 Nov 01; 35(11):1529-39. PubMed ID: 23115402
    [Abstract] [Full Text] [Related]

  • 13. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.
    Clin Ther; 2005 Aug 01; 27(8):1181-95. PubMed ID: 16199244
    [Abstract] [Full Text] [Related]

  • 14. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
    Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH.
    Obes Res; 2003 Jun 01; 11(6):722-33. PubMed ID: 12805393
    [Abstract] [Full Text] [Related]

  • 15. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.
    Diabetes Obes Metab; 2003 May 01; 5(3):180-8. PubMed ID: 12681025
    [Abstract] [Full Text] [Related]

  • 16. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
    Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME.
    Clin Ther; 2007 Jan 01; 29(1):139-53. PubMed ID: 17379054
    [Abstract] [Full Text] [Related]

  • 17. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW.
    Lancet; 2011 Apr 16; 377(9774):1341-52. PubMed ID: 21481449
    [Abstract] [Full Text] [Related]

  • 18. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
    Tremblay A, Chaput JP, Bérubé-Parent S, Prud'homme D, Leblanc C, Alméras N, Després JP.
    Eur J Clin Pharmacol; 2007 Feb 16; 63(2):123-34. PubMed ID: 17200837
    [Abstract] [Full Text] [Related]

  • 19. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J.
    Diabetes Obes Metab; 2000 Apr 16; 2(2):105-12. PubMed ID: 11220522
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A, Winterholer S, Jeitler K, Horvath K, Berghold A, Krenn C, Semlitsch T.
    Cochrane Database Syst Rev; 2021 Jan 17; 1(1):CD007654. PubMed ID: 33454957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.